Vitalhub Corp. (TSE:VHI - Get Free Report)'s stock price dropped 1.5% during mid-day trading on Friday . The company traded as low as C$10.45 and last traded at C$10.78. Approximately 184,327 shares were traded during trading, an increase of 10% from the average daily volume of 167,340 shares. The stock had previously closed at C$10.94.
Analysts Set New Price Targets
A number of analysts recently issued reports on VHI shares. TD Securities raised Vitalhub to a "strong-buy" rating in a report on Monday, November 25th. Cormark raised their price objective on shares of Vitalhub from C$9.50 to C$10.50 and gave the company a "buy" rating in a research report on Wednesday, October 2nd.
Check Out Our Latest Research Report on Vitalhub
Vitalhub Stock Down 1.5 %
The firm has a market capitalization of C$548.16 million, a PE ratio of 98.00, a PEG ratio of 1.18 and a beta of 1.26. The company has a 50-day moving average of C$10.91 and a 200 day moving average of C$9.16.
About Vitalhub
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Read More
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.